The latest study showed that quinoline-2-carboxylic acid in Ephedra could effectively antagonize the active compounds produced by the interaction between angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2 spike protein receiver binding domain (SARS-CoV-2 RBD) and inhibit the viral infection, thus showing the potential of using Ephedra to treat COVID-19 infection [115]. Here, ACE2 is linked to viral infectious disease.